Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

6 treatments under study, led by Zileuton

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed with results

Key Signals

2 with results50% success

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Unknown1
Completed1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05529394UnknownPrimary

Effect of Storage Condition on CD47 Expression Level in Platelet Concentrate

NCT00001596Phase 2Completed

Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome

NCT00467831Phase 1/2Terminated

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

Showing all 3 trials

Research Network

Common Treatments

  • Zileuton1
  • Acetylcysteine1
  • Erythromycin1
  • Losartan1
  • Pravastatin1

Active Sponsors

  • National Human Genome Research Institute (NHGRI)2
  • William Gahl, M.D.1
  • Assiut University1

Top Investigators

Related Conditions

  • Oculocutaneous Albinism2
  • Pulmonary Fibrosis2
  • Albinism1
  • Hermanskypudlak Syndrome Hps1
  • Inborn Errors Of Metabolism1

Activity Timeline